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Abstract
Background: Monitoring low molecular weight heparins (LMWH’s) in the perioperative period is prudent in
patients at high risk of coagulative complications, especially when the patient has an epidural catheter requiring
withdrawal, which is associated with the risk of spinal haematoma. The aim of this study was to evaluate the in
vitro dose-responses of two different LMWH’s on two different viscoelastic haemostatic tests, using blood sampled
from patients with normal routine coagulation parameters, on the day after major surgery when their epidural
catheters were due to be withdrawn.
Methods: Enoxaparin or tinzaparin were added in vitro to blood from ten patients who had undergone
oesophageal resection, to obtain plasma concentrations of approximately 0, 0.5, 1.0 and 1.5 IU/mL. Coagulation
was monitored using thromboelastometry (ROTEM®) using the InTEM® activating reagent; and free oscillation
rheometry (FOR: ReoRox®), activated using thromboplastin. Clot initiation was measured using ROTEM-CT,
ReoRox-COT1 and ReoRox–COT2. Clot propagation was measured using ROTEM-CFT, ROTEM-Alpha Angle and
ReoRox-Slope. Clot stability was measured using ROTEM-MCF and ReoRox-G’max, and clot lysis was measured
using ROTEM-ML and ReoRox-ClotSR.
Results: Clot initiation time assessed by thromboelastometry and FOR was prolonged by increasing
concentrations of both LMWH’s (P < 0.01). Equivalent doses of tinzaparin in international units (anti-FXa units)
per millilitre prolonged clot initiation more than enoxaparin (P < 0.05). There was significant inter-individual
variation – the ranges of CT and COT1 at LMWH-concentrations of 0 and 1.5 IU/mL overlapped. None of the
tests reflecting clot formation rate or stability showed a dose–response to either LMWH but clot lysis showed a
tentative negative dose–response to the LMWH’s.
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Conclusions: Clot initiation time’s dose-dependent prolongation by LMWH’s in this study agrees with previous
research, as does tinzaparin’s stronger anti-coagulative effect than enoxaparin at equivalent levels of anti-FXa
activity. This casts doubt on the validity of using anti-FXa assays alone to guide dosage of LMWH’s. The significant
inter-individual variation in dose–response suggests that the relationship between dose and effect in the
postoperative period is complicated. While both ROTEM and FOR may have some role in postoperative
monitoring, more research is needed before any conclusion can be made about their clinical usefulness.
Keywords: Coagulation, Factor Xa, Thromboelastometry, Free-oscillation rheometry, Low molecular weight
heparin, Postoperative, Enoxaparin, Tinzaparin, Epidural haematoma, Spinal haematoma
Background
When low molecular weight heparins (LMWH’s) were
first used in clinical practice, monitoring was considered
unnecessary [1], but this has recently been questioned
since major haemorrhagic complications are regularly
reported in patients treated with LMWH and the opti-
mal LMWH dose in the aged, patients with obesity and
renal insufficiency is not well defined [2–4]. Hypercoa-
gulative states are common in many settings: postopera-
tive, critical illness, obstetrics, oncology and coronary
care; such that ordinary doses of LMWH are insufficient,
but overdosing of thrombosis prophylaxis is also danger-
ous since it predisposes to haemorrhagic complications
such as spinal haemorrhage in conjunction with with-
drawing an epidural catheter [4–8].
Low molecular weight heparins have more predictable
pharmacokinetic and pharmacodynamic properties than
unfractionated heparin (UFH), and have therefore become
the gold standard in many clinical situations such as
thromboprophylaxis, and treatment of deep vein throm-
bosis (DVT) and pulmonary embolism (PE). Variation in
the anticoagulant potency of the numerous LMWH’s that
are available is the result of different degrees of inhibition
of coagulation factors Xa and IIa. LMWH’s with greater
molecular weight are more similar to unfractionated hep-
arin [1, 9, 10]. UFH (mean molecular weight, MW,
15 kDa) inhibits factor Xa and IIa equally whereas enoxa-
parin (mean MW 4.2 kDa) is a LMWH with a high anti-
FXa/anti-FIIa ratio: it inhibits factor Xa four times as
strongly as IIa. Tinzaparin (mean MW 6.8 kDa) is more
similar to unfractionated heparin in that it inhibits factor
Xa only twice as strongly as factor IIa [11].
Routine laboratory plasma based coagulation tests for
monitoring heparinization, such as the activated partial
thromboplastin time (aPTT), and the chromogenic anti-
FXa test only detect changes in the initiation phase of
coagulation and are not always rapidly available at all
times of the day. It is possible to run viscoelastic haemo-
static tests (VHT’s) in ‘patient-near’ laboratories or even
bedside at any time of the day, providing preliminary
results within minutes and complete results within an
hour of blood sampling. There are several commercially
available VHT’s which allow analysis not only of the
propagation and amplification phases of whole blood
coagulation, but also of fibrinolysis and clot structure,
which depend upon fibrin polymerization and platelet
activity [12, 13].
It would be advantageous to be able to titrate LMWH
doses using viscoelastic tests to reduce complications
caused by bleeding and thrombosis. However, there are
few studies in this area and to our knowledge there are
no studies concurrently comparing different LMWH’s
with different anti-FXa/anti-FIIa ratios, using different
VHT’s [14–16].
The aim of this study was to evaluate dose–response
effects of enoxaparin and tinzaparin on ROTEM® and
FOR: can these instruments be used to monitor
LMWH’s at and above levels used for thrombosis
prophylaxis? Our hypothesis was that FOR would be
more sensitive to LMWH’s effects on clot formation and
strength than thromboelastometry.
Methods
Study subjects and sampling
Ten patients who had undergone oesophageal resection
were included in the study after informed and signed
consent. The study was approved by the local ethics
committee in Lund (DNR 2010/482-100).
Blood was sampled from each patient’s indwelling cen-
tral venous catheter on the day that their epidural catheter
was removed, using 4.5 mL BD Vacutainer® citrate tubes.
All patients had been routinely sampled the day before to
assure normal renal function (creatinine, urea), routine
coagulation parameters: activated partial thromboplastin
time (aPTT), prothrombin time international normalized
ratio (PT-INR) and platelet count (PLT). All patients had
received standard thrombosis prophylaxis with enoxaparin
40 mg at 8 p.m. the evening before blood sampling, which
took place between 10 a.m. and 2p.m, 14–18 h after the
last dose of enoxaparin.
Titration of blood with LMWH
Enoxaparin (Klexane, Sanofi-Aventis, Guildford, UK)
and tinzaparin (Innohep, Leo Pharma, Ballerup,
Thomas et al. BMC Anesthesiology  (2015) 15:170 Page 2 of 10
Denmark) were diluted with isotonic saline (9 mg/mL
NaCl: Fresenius Kabi, Bad Homburg, Germany) to con-
centrations of 10, 20 and 30 IU/mL. 60 μL aliquots of
saline containing 0, 10, 20 or 30 IU/mL enoxaparin or
tinzaparin were then added to 2 mL portions of pre-
warmed (37 ° C) citrated blood from each patient to ob-
tain plasma concentrations of 0, 0.5, 1.0 and 1.5 IU/mL
of enoxaparin and tinzaparin, respectively, assuming that
the blood samples had a haematocrit of 40 %. The sam-
ples were incubated for 10 min at 37 °C.
The concentrations of LMWH between 0 and 1.5 IU/ml
in this study encompass both thromboprophylactic levels
of 0.2-0.4 IU/mL, and higher anti-FXa levels that are
above recommended levels [17].
Viscoelastic coagulation analysis
Clot formation and lysis was studied using thromboelas-
tometry (ROTEM®, Pentapharm, Munich, Germany) and
FOR (ReoRox G2®, MediRox, Nyköping, Sweden). Ana-
lyses were run at 37 °C within 1 h of sampling.
Thromboelastometry
Technical details on ROTEM have been described previ-
ously [18, 19]. Briefly, the ROTEM® has a fixed sample
cup with a pin suspended in the blood sample. The pin
oscillates and the movement is registered in the coagu-
lating sample [18]. Analysis of coagulation with ROTEM
gives rise to a curve from which the clotting time (CT),
clot formation time (CFT), alpha angle, maximum clot
firmness (MCF) and maximum clot lysis (ML), which
represents fibrinolysis, can be determined as shown in
Fig. 1 [19].
After addition of 20 μL of 0.2 M CaCl2 (the ‘star-tem®’
reagent) to 300 μL of each sample, coagulation was initi-
ated in each sample by addition of 20 μL of the InTEM®
reagent, which contains partial thromboplastin phospho-
lipid and ellagic acid.
Free oscillation rheometry (FOR)
FOR was assessed with the ReoRox G2 rheometer
(MediRox AB, Nyköping, Sweden). The sample is
added to a reaction chamber which consists of a
gold-coated sample cup with a gold-coated cylinder
suspended in the blood sample [20]. The sample cup
oscillates and the changes in the frequency and
damping of the oscillation in the coagulating sample
are registered. Changes in damping give rise to a vis-
cosity curve measured in Pascal-seconds (Pa.s) against
time and changes in frequency give an elasticity curve
measured in Pascals (Pa) against time, as shown in Fig. 1.
The clotting time (COT) can be obtained from the viscos-
ity curve: COT1 represents the time to initiation of clot
formation and COT2 the time when clot formation is
complete and elasticity starts developing. COT2 is equiva-
lent to ROTEM’s CT. The difference between COT2 and
COT1 is a measure of clot progression. From the elasticity
curve the slope, maximum elasticity (G’max; the max-
imum strength/stiffness of the clot) and clot strength re-
duction (Clot SR; fibrinolysis) can be determined. These
correspond to ROTEM’s alpha angle, MCF or MCE and
ML, respectively.
After addition of 25 μL of 0.5 M CaCl2 (MediRox AB)
to 1000 μL of sample, coagulation was initiated with
thromboplastin (the HepScreen1 reagent, MediRox AB).
The FOR tracings analyzed were: COT1, COT2, slope,
G’max and Clot SR.
Statistical analysis
The ‘R’ Statistical environment (version 3.1.3: www.r-
project.org) was used for statistical calculation and to cre-
ate diagrams. Correlations were tested using Spearman’s
test. The significances of differences between results
for different levels of heparinization using the same
LMWH and different LMWH’s at the same level of
heparinization were tested using the Wilcoxon signed
Fig. 1 Diagram showing the parameters recorded from rotational thromboelastometry (ROTEM) and free oscillation rheometry (FOR, ReoRox).
(a) ROTEM. (b) ReoRox. A brief explanation of the parameters follows: measures of clot initiation: ROTEM-CT (clot time) and FOR-COT1 and -COT2.
Measures of clot propagation: ROTEM-CFT and –alpha angle; and FOR-(COT2-COT1) and –Slope. Measures of clot structure: ROTEM-MCF and
FOR-G’max. Measures of fibrinolysis: ROTEM-ML and FOR-Clot SR
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rank test. A P-value of <0.05 was considered signifi-
cant. Friedman’s analysis of variance was used to de-
tect significant differences in the distributions of
results for enoxaparin and tinzaparin, taking into ac-
count inter-individual variation and differing concen-
trations of LMWH. Box and whisker diagrams were
constructed using R’s boxplot function. Boxes span
the interquartile range and the whiskers encompass
the data point furthest from the box yet within 1.5
times the length of the box from the box.
Results
Raw data of our results are available as a text file in
‘Additional file 1’.
Measures of clot initiation were prolonged by increasing
doses of LMWH
Measures of initiation of coagulation as assessed by
ROTEM and FOR were significantly prolonged by in-
creasing concentrations of both LMWH’s (ROTEM-
CT, FOR-COT1 and FOR-COT2: see Table 1 and
Fig. 2a-c), with significant correlation coefficients
(Spearman’s Rho) of between 0.54 and 0.77, but there
was a wide spread of results, with the lowest mea-
sured ROTEM-CT in the presence of 1.5 IU/mL tin-
zaparin being shorter than the longest ROTEM-CT in
the control group (0 IU/mL tinzaparin). The two
LMWH’s values of ROTEM-CT correlated to each
other significantly, as did their values of FOR-COT1
and FOR-COT2 (see Figs. 3a,b and d).
FOR-(COT2-COT1) was the only measure of clot
propagation that showed a dose–response to LMWH
ROTEM-alpha angle, ROTEM-CFT and FOR-Slope were
not affected by increasing concentrations of LMWH (see
Table 1 and Fig. 2d and g). FOR-(COT2-COT1), which
is the time delay between when viscosity starts to in-
crease (COT1) and when elasticity starts to increase
(COT2), was significantly prolonged by increasing doses
of LMWH. The median (COT2-COT1) in the presence
of 1.5 IU/mL tinzaparin and enoxaparin were 50 % and
30 % respectively longer than in the absence of added
LMWH, giving correlation coefficients (Spearman’s Rho)
of 0.47 and 0.79 respectively (P < 0.05). Although the dif-
ferences between (COT2-COT1) for the two LMWH’s at
each concentration were not significantly different, there
was a significant whole-data difference in the results
for tinzaparin and enoxaparin (see Table 1 and
Fig. 2h). ROTEM-MCF and FOR-G’max for enoxa-
parin and tinzaparin showed good correlation (see
Fig. 3e-f ) but were not affected by increasing doses of
either LMWH (see Table 1).
ROTEM and FOR’s tests for clot lysis showed a tentative
dose response
Neither our ROTEM-ML nor FOR-ClotSR results were
outside the reference ranges for a normal level of fibrin-
olysis, and there were no significant differences between
enoxaparin and tinzaparin at any concentration, or in
ANOVA whole-data analysis. There was, however, a sig-
nificant but weak negative correlation between the dose
of enoxaparin and ROTEM-ML (σ = −0.36, P < 0.05);
and the dose of tinzaparin and FOR-Clot SR (σ = −0.41,
P < 0.05), but not between the dose of enoxaparin and
FOR-Clot SR or tinzaparin and ROTEM-ML (see Table 1
and Fig. 2e and f).
Discussion
Miyazaki et al. estimated that around 70 % of spinal he-
matomas occurring at the time of withdrawing an epi-
dural catheter were related to abnormal coagulation,
which challenges the dogma that monitoring of prophy-
lactic LMWH is unnecessary in this setting [7]. Due to
the difficulty and expense involved in conducting pro-
spective studies on rare complications, it is very unlikely
that such a study will ever be able to show that visco-
elastic tests are reliable predictors of spinal haematoma.
The most common and well-documented clinical visco-
elastic tests are thrombelastography (TEG®) and rotational
thromboelastometry (ROTEM®). Less well-documented
are free oscillation rheometry (FOR, ReoRox®) and
Sonoclot® [12, 13, 21]. Although these assays measure
the same aspects of coagulation and can detect both
hypocoagulation and hypercoagulation, they differ in
their mechanisms [21–23].
LMWH’s are a diverse group of antithrombotic mole-
cules derived from unfractionated heparins (UFH) and
have different structures and molecular weights (MW’s),
which results in varying pharmacological features [24]. In
this study coagulation following treatment with LMWH’s
(enoxaparin and tinzaparin) was assessed using viscoelas-
tic methods (thromboelastometry and FOR) to assess their
potential to monitor treatment with LMWH’s.
Previous studies have shown varying abilities of
viscoelastic devices to monitor treatment with
LMWH’s [15, 16, 25–27] whereas UFH has been success-
fully monitored in healthy volunteers [27]. Louis et al. re-
cently failed to show that the rate of deep vein thrombosis
rate in trauma patients was reduced by using TEG trac-
ings to titrate enoxaparin doses despite this leading to an
increase in anti-FXa activity [28].
Both ROTEM and FOR show a linear relationship between
measures of clot initiation and concentration of LMWH,
albeit with great inter-individual variation
We found that both LMWH substances prolonged both
instruments’ measures of clot initiation in a significant
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Table 1 Rotational thromboelastometry (ROTEM) and free-oscillation rheometry (FOR) results at varying concentrations of enoxaparin and tinzaparin
Manufacturer’s
reference range
0 IU/mL Enoxaparin Enoxaparin Enoxaparin Tinzaparin Tinzaparin Tinzaparin Enoxaparin vs Tinzaparin Enoxaparin Tinzaparin
0.5 IU/mL 1.0 IU/mL 1.5 IU/mL 0.5 IU/mL 1.0 IU/mL 1.5 IU/mL ANOVA❖ Spearman (Rho, P) Spearman (Rho, P)
ROTEM
CT (s) 100-240 178 ± 38 191 ± 89 214 ± 109 249 ± 94 223 ± 53 289 ± 84 326 ± 125 P < 0.01 0.62, P < 0.01 0.70, P < 0.01
CFT (s) 30-110 77 ± 23 87 ± 21 85 ± 16 83 ± 22 74 ± 27 84 ± 45 80 ± 21 P < 0.05 N/S N/S
Angle (°) 70-83 75 ± 4 74 ± 4 75 ± 3 73 ± 4 75 ± 5 73 ± 5 73 ± 4 N/S N/S N/S
MCF (mm) 50-72 62 ± 5 61 ± 7 63 ± 5 63 ± 6 68 ± 7 64 ± 8 65 ± 6 N/S N/S N/S
ML (%) <15 8 ± 4 6 ± 3 5 ± 4 2 ± 5 5 ± 4 6 ± 4 2 ± 4 N/S −0.36, P < 0.05 N/S
FOR (ReoRox)
COT1 (s) 20-35 30 ± 5 35 ± 7 39 ± 8 38 ± 11 36 ± 4 45 ± 9 48 ± 15 P < 0.01 0.58, P < 0.01 0.77, P < 0.01
COT2 (s) 30-90 65 ± 11 76 ± 13 82 ± 14 85 ± 20 74 ± 5 91 ± 16 108 ± 29 N/S 0.54, P < 0.01 0.84, P < 0.01
COT2-COT1 (s) 10-55 34 ± 13 41 ± 8 43 ± 9 46 ± 10 38 ± 4 46 ± 11 51 ± 15 P < 0.05 0.47, P < 0.01 0.79, P < 0.01
Slope (Pa/min) 45-145 99 ± 87 121 ± 82 126 ± 88 132 ± 76 118 ± 90 138 ± 94* 109 ± 88 P < 0.01 N/S N/S
G’max (Pa) 770-2180 1629 ± 617 1777 ± 662 1831 ± 701 1612 ± 612 1656 ± 692 2069 ± 665 1615 ± 641 N/S N/S N/S
Clot SR (%) 10-25 17 ± 4 14 ± 5 16 ± 4 13 ± 6 15 ± 5 13 ± 6 11 ± 7 N/S N/S −0.41, P < 0.05
Results are presented as median ± SD. The significances of differences between individual concentrations, and between enoxaparin and tinzaparin at equal concentrations, are shown in Figs. 2 and 3, which display the
results diagrammatically. ❖The significance of differences between results for enoxaparin and tinzaparin, corrected for concentration and individual, were assessed by Friedman’s analysis of variance (ANOVA). A brief
explanation of the above tests follows. Measures of clot initiation: ROTEM-CT (clot time) and FOR-COT1 and -COT2. Measures of clot propagation: ROTEM-CFT and –alpha angle; and FOR-(COT2-COT1) and –Slope.
Measures of clot structure: ROTEM-MCF and FOR-G’max. Measures of fibrinolysis: ROTEM-ML and FOR-Clot SR













Fig. 2 (See legend on next page.)
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dose-dependent manner, suggesting possible useful-
ness for postoperative monitoring. FOR measures
both the time to initiation of increasing viscosity
(COT1), reflecting early clot initiation and the time
to increasing elasticity (COT2), which corresponds to
ROTEM-CT. All these parameters increased signifi-
cantly with increasing doses of LMWH’s, which is in
agreement with previous research [16].
Whether the great inter-individual variation that we
observed precludes these techniques use in monitoring
(See figure on previous page.)
Fig. 2 Box and whisker plots showing rotational thromboelastometry (ROTEM) and free-oscillation rheometry (FOR) results for enoxaparin and
tinzaparin at varying concentrations. A brief explanation of the parameters follows: measures of clot initiation: ROTEM-CT (clot time) (a) and
FOR-COT1 (b) and -COT2 (c). Measures of clot propagation: ROTEM-CFT (g); and FOR-(COT2-COT1) (h) and –Slope (d). Measures of fibrinolysis::
ROTEM-MCL (e) and FOR-ClotSR (f). *indicates a significant difference with p < 0.05. **indicates a significant difference with p < 0.01. Panels inside
the figures both reflect inter- and intra-group comparisons
Fig. 3 Scatter plot comparing ROTEM and FOR results at corresponding doses of enoxaparin and tinzaparin in IU/mL. Results are tightly and
significantly correlated but tinzaparin has a stronger anticoagulative effect than enoxaparin at any given concentration. This is due to tinzaparin
having a lower anti-FXa/anti-FIIa ratio than enoxaparin: for each unit of anti-FXa activity, tinzaparin has more anti-FIIa effect than enoxaparin.
Rho: Spearman’s Rho: see methods section. A brief explanation of the parameters follows: measures of clot initiation: ROTEM-CT (clot time)
(a) and FOR-COT1 (b) and -COT2 (d). Measures of clot propagation: ROTEM-CFT (c). Measures of clot structure: ROTEM-MCF (e) and FOR-G’max (f)
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LMWH’s depends on whether the results actually reflect
the coagulation status of the patients or not: although
methodological variation may account for some of the
variation, the complex coagulation status occurring after
major surgery is also likely to cause variation in patients’
response to any given dose of LMWH and it is possible
that viscoelastic tests have a place in identifying ‘sensi-
tive’ patients for whom a ‘normal dose’ is actually an
overdose: preoperative malnourishment results in a re-
duced capacity to produce vitamin K dependent coagula-
tion factors, and a major inflammatory response to
surgery can be expected to cause shifts in plasma levels
of coagulation factors. Shifts in fluid balance in the after-
math of haemorrhage with or without excessive transfu-
sion can cause unpredictable variations in renal function
and thereby pharmakokinetics. The postoperative state
generally predisposes to hypercoagulation [29]. It is
tempting to attribute the great inter-individual variation
detected in this study exclusively to varying ‘postopera-
tive factors’, but the results are actually in agreement
with results from healthy volunteers given a direct factor
Xa inhibitor by Casutt et al. in 2012 [30]. This is clearly
an under-researched area of perioperative medicine and
deserves more attention.
Neither ROTEM nor FOR could detect that LMWH affected
clot stability
We observed no significant correlation between the
concentration of LMWH and maximum clot strength
(ROTEM-MCF and CFT, and FOR-Slope and G’max),
see Fig. 2 and Table 1. This confirms previous work by
Feuring et al., who observed that ROTEM-MCF was only
affected by supratherapeutic levels of dalteparin; but is in
contrast to Gerotziafas et al. who found that therapeutic
doses of enoxaparin did indeed affect TEG-MA (throm-
belastography maximum amplitude, corresponds to
ROTEM-MCF) in healthy volunteers [25, 31]. LMWH
consistently impedes clot initiation as measured by visco-
elastic tests but not clot propagation or structure, but this
does not necessarily mean that LMWH does not affect
clot propagation in vivo since both the ex vivo viscoelastic
tests discussed in this article are flawed by the fact that
they monitor coagulation in a stagnant container. In vivo
coagulation takes place within or beside blood vessels in
which there is blood flow. If clot initiation is too slow in a
microenvironment where there is constant flow, the clot
may be ‘washed away’ before it has even formed. In
contrast, even a very slow-forming clot in a viscoelastic
test container is able to contribute to the cell mediated
positive-feedback loops that maintain propagation.
We had hypothesised that FOR might be more sensi-
tive to LMWH’s possible attenuations of clot propaga-
tion and maximum amplitude, but this could not be
confirmed by our results. Our hypothesis was based on
the knowledge that the shear forces applied by rotational
thromboelastometry are known to exceed the linear
viscoelastic properties of clots and may therefore in
themselves weaken the developing clot [32]. FOR, how-
ever, does not apply shear force to the sample: it applies
a short oscillation every 2.5 s instead, which allows
measurement of both viscosity and elasticity, and should
also disturb the clot less than ROTEM [33]. Other dif-
ferences between the techniques that may lead to differ-
ing patterns of contact activation are that the reagents
used to initiate coagulation are different: ROTEM® uses
thromboplastin phospholipid and ellagic acid whereas
ReoRox® uses thromboplastin alone, potentially resulting
in different patterns of activation. The surfaces in the
ROTEM® chamber are plastic while ReoRox® is gold-
plated, which may affect initiation of coagulation and
reduce the tendency of the clot to loosen from the cup
wall giving a false impression of fibrinolysis.
The dose-effect observed on fibrinolysis was only
tentative, and surprisingly suggested that increasing
doses of LMWH’s decreased fibrinolysis
Although the statistical significance of the dose-effect of
LMWH’s on measures of fibrinolysis were only tentative,
Fig. 2e and f show a negative dose–response that may
deserve further investigation. Previous findings suggest
that LMWH’s increase rather than decrease fibrinolysis
[34]: it is an interesting hypothesis that the postoperative
coagulative environment may provide conditions where
the inverse is true.
Tinzaparin is more potent than enoxaparin and the two
LMWH’s measureable effects in this study are linearly
correlated. We again question anti-FXa activity’s ‘gold
standard status’ for monitoring LMWH
We found significant correlations between tinzaparin and
enoxaparin for several ROTEM and FOR parameters.
However, all the parameters for which a dose–response
could be demonstrated in this study showed that tinza-
parin had a stronger anticoagulant effect than a corre-
sponding dose of enoxaparin in international units per
millilitre (see Fig. 2 and 3). This is in line with our previ-
ous findings where tinzaparin has been shown to prolong
aPTT and impede thrombin generation to a greater degree
than enoxaparin, and as explained previously is due to tin-
zaparin having a lower anti-FXa/anti-FIIa ratio than enox-
aparin. If the two LMWH’s are dosed in equal units of
anti-FXa activity (‘international units’), the tinzaparin will
have a stronger overall anticoagulant effect due to the
anti-IIa activity which accompanies each unit of anti-FXa
activity [11]. There is also evidence that UFH and
LMWH’s with larger molecular weight (>2 kDa) exert an
anticoagulant effect through plasma tissue factor pathway
inhibitor [35].
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At many institutions, including our own institution,
the anti-FXa activity assay has become the clinical ‘gold
standard’ for monitoring LMWH’s. Although anti-FXa
activity is likely a reliable measure of LMWH concentra-
tion [36], we would advise against relying on this assay
alone to titrate the dose of LMWH: we suggest that sev-
eral assays (anti-FXa, aPTT, antithrombin, viscoelastic
tests, possibly thrombin generation) should be run con-
currently and in series. Laboratory results should be
combined with clinical judgement to dose LMWH’s in
patients at risk of thromboembolic or haemorrhagic
complications, particularly in patients where haemor-
rhage could be catastrophic, such as those whose
epidural catheter is due to be withdrawn. This is not
particularly new: in 2009 Van et al. observed that throm-
belastography was a better predictor of deep vein throm-
bosis than anti-FXa activity in trauma and surgical
patients [14].
Limitations of this study
There are some limitations to this study: it is a small in
vitro dose–response study and should thus be viewed as
a pilot study with low specificity. Since all our patients
are given LMWH to prevent postoperative thrombo-
embolism, it was not possible to run tests on a control
group that had been exposed to major surgery but not
LMWH. While preoperative ‘baseline’ analyses could
have been taken, they could potentially have been mis-
leading since LMWH is only one of the factors affecting
postoperative coagulation.
A criticism of the method could be that we did not
test for the samples’ haematocrits and adjust the doses
of LMWH accordingly: a lower haematocrit means a
greater fraction of plasma in the sample, and therefore a
greater ‘volume of distribution’ for the LMWH that we
added. We nevertheless decided to administer LMWH
to our samples in standard doses because this is what
happens in clinical practice: LMWH is either prescribed
in standard doses or by weight, which are rarely adjusted
for renal function or haematocrit.
Conclusions
Both ROTEM and FOR showed clot-initiation to be pro-
longed by increasing doses of both LMWH’s albeit with
significant inter-individual variation, which may preclude
their use in monitoring LMWH in the postoperative
period: it is unclear from this study whether the inter-
individual variation was due to methodological variation
or ‘true’ pharmacodynamic variation. The dose–response
was, as expected, significantly greater for tinzaparin than
enoxaparin at equivalent doses of anti-Xa activity. We
could not confirm our hypothesis that FOR could meas-
ure LMWH’s effects on other measures of coagulation
more sensitively than rotational thromboelastometry.
More research is needed before any conclusion can be
made about the superiority of ROTEM or FOR in indi-
vidualizing thromboprophylactic or therapeutic therapy
with LMWH.
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